Google
Trusted Resources: News & Events
Latest announcements and gatherings
Emmaus Medical, Inc. Selects AmerisourceBergen to Support the Launch of EndariTM (L-glutamine oral powder)
AmerisourceBergen, a global healthcare solutions leader, today announced that US Bioservices, an independent specialty pharmacy, has been selected by Emmaus Medical, Inc. as the specialty pharmacy for EndariTM (L-glutamine oral powder), for the treatment of patients with sickle cell disease.
The U.S. Food and Drug Administration approved Endari on July 7, 2017 for adult and pediatric patients 5 years of age and older to reduce acute complications of sickle cell disease. Endari is the first approved treatment for sickle cell disease in pediatric patients and the first new treatment available in nearly 20 years for adults.
As part of this partnership, Emmaus will leverage the breadth of AmerisourceBergen’s integrated commercialization solutions to support adherence and realize the best possible outcomes for patients. In addition to utilizing the comprehensive clinical services of US Bioservices, Emmaus will also collaborate with AmerisourceBergen’s ASD Healthcare and ICS.
+myBinderRelated Content
-
Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional...Serial phlebotomy was performed on sixty...
-
Magnesium for treating sickle cell diseaseBACKGROUND: Sickle cell disease is an a...
-
Sickle cell patients in UK survey, especially those 16 to 20, voice problems with care and pain relief givenIn a survey, patients across the...
-
Step toward gene therapy for sickle cell diseaseA team of researchers at the Stanford Un...
-
FDA Advisory Committee Recommends Approval of Endari™ from Emmaus Life Sciences for the Treatment of Sickle Cell D...Emmaus Life Sciences Inc. announced toda...
-
Treatment Advances in Sickle Cell Disease, Amber M. Yates, MDhttps://www.youtube.com/watch?v=oFIOKC4r...
-
Phase 3 Trial of Rivipansel in Treating SCD Pain Crisis Fails to Meet Goals, Pfizer AnnouncesThe Phase 3 RESET trial testing the effe...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.